Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Before High-Dose Chemotherapy BEAM With Autologous Stem Cell Transplantation (ASCT)

NCT02374424 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.

NCT NCT02374424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02374424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Before High-Dose Chemotherapy BEAM With Autologous Stem Cell Transplantation (ASCT)
Lead sponsor
Fondazione Italiana Linfomi - ETS
Phase
Phase 2
Overall status
Terminated
Start date
November 5, 2014
Completion date
June 23, 2020
Enrollment
29 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse, large b-cell, lymphoma